Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.
暂无分享,去创建一个
Pinaki Biswas | P. Biswas | P. Glue | B. Damle | P. Crownover | Paul Glue | Chang Lin | Bharat D Damle | Howard Uderman | Penelope Crownover | H. Uderman | Chang Lin
[1] France Mentré,et al. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. , 2008, British journal of clinical pharmacology.
[2] S. Spector,et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children , 2005, AIDS.
[3] P. Glue,et al. Significant Decrease in Nelfinavir Systemic Exposure After Omeprazole Coadministration in Healthy Subjects , 2008, Pharmacotherapy.
[4] A. Patick,et al. Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities , 2001, Antimicrobial Agents and Chemotherapy.
[5] M. Siddiqui,et al. Nelfinavir , 2012, Drugs.
[6] D. Burger,et al. The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir. , 2006, British journal of clinical pharmacology.
[7] P. Wedlund. The CYP2C19 Enzyme Polymorphism , 2000, Pharmacology.
[8] Jacques Fellay,et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.
[9] M. Hirsch,et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. , 2005, The Journal of infectious diseases.
[10] J. Lasker,et al. CONVERSION OF THE HIV PROTEASE INHIBITOR NELFINAVIR TO A BIOACTIVE METABOLITE BY HUMAN LIVER CYP2C19 , 2004, Drug Metabolism and Disposition.
[11] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.
[12] Kaori Ito,et al. Effects of Standard and Supratherapeutic Doses of Nelfinavir on Cardiac Repolarization: A Thorough QT Study , 2009, Journal of clinical pharmacology.
[13] J. Paulauskis,et al. Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First‐ and Third‐generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations , 2008, Clinical pharmacology and therapeutics.
[14] J. Gerber,et al. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] R. Maserati,et al. Clinical Pharmacokinetics of Nelfinavir and Its Metabolite M8 in Human Immunodeficiency Virus (HIV)-Positive and HIV-Hepatitis C Virus-Coinfected Subjects , 2005, Antimicrobial Agents and Chemotherapy.